GUILD Learning and Development (formerly the Guild Pharmacy Academy) has partnered with Boehringer Ingelheim, sponsors of Spiriva Respimat and Spiolto Respimat, in the development of an online course which addresses the pathophysiology, detection and treatment goals of chronic obstructive pulmonary disease (COPD) and the role pharmacists can play in COPD management.
COPD is a common, preventable and treatable condition that affects about 13% of Australians aged 40 years or over, with almost half of sufferers experiencing impaired quality of life, the Guild says.
This CPD-approved-course provides pharmacists with a clinical review of the treatment of COPD and the pharmacological and non-pharmacological approaches to managing COPD.
Visit www.myCPD.org.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Mar 17
